Biotech’s ~10-year path from private risk to approved therapy is mismatched with trading-driven capital markets, where minor ...

David Crean, chief business officer at MedicNova, discusses changes at FDA causing variability and unpredictability in ...

In the third part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, traces the origins of ...

It’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact. In the age of digital dominance, social ...

An exclusive China launch collaboration positions CTTQ to lead importation, distribution, hospital access, and promotion, while GSK retains marketing authorization and oversight of regulatory, quality ...

In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...

ATTAIN-Maintain found oral orforglipron preserved prior loss after injection-to-oral transition, with only 0.9 kg regain from ...

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and ...

Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...

White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...